Fisher Scientific's third-quarter revenues swelled to $1.2 billion from $890 million in the third quarter of 2003. Revenues from scientific products and services rose to $945 million from $632 million year over year.
Sales of scientific products and services in the recent quarter totaled $922.8 million, an increase of 46 percent compared to the third quarter of 2003.
Apogent and Oxoid, the company's molecular biology-supply unit, and Dharmacon, a recent acquisition, contributed revenue to Fisher's scientific products and services income. However, the Hampton, NH-based firm did not break out revenues by unit.
Net income dropped to $10.8 million, or $.10 per diluted share, from $27.7 million, or $.47 per share, year over year.
Fisher reported $296.4 million in cash and cash equivalents available on Sept. 30, part of the company's $7.9 billion of total assets.